According to the findings of new clinical studies, the administration of high dose immunosuppressive therapy, accompanied by transplantation of an individual’s blood-forming stem cells, has the potential to induce sustained remission of the autoimmune disease – multiple sclerosis.
In a clinical trial that was sponsored by the National Institute of Allergy and Infectious Diseases, 69 percent of the participants exhibited decreased progression of disability and reduced relapses of the symptoms of multiple sclerosis. Upon receiving HDIT/HCT, the trial participants did not take any other MS medications. Based on this study, and numerous others, MS drugs portray lower success rates. On the other hand, the extended findings of this study suggest that a single treatment using HDIT/HCT is more effective compared to long-term treatments using the best medications available to people suffering from a given type of MS, as explained by the director of NIAID, Anthony S. Fauci, M.D.
The primary objective of the experimental treatment is to suppress active disease, and also prevent further disability into ways; by eliminating the disease-causing cells, and by resetting the immune system. The doctors collect the blood-forming cells of the participant, administer to the participant high dose chemotherapy to expand the immune system and then return the stem cells of the participant to stimulate reconstruction of the immune system. Richard Nash, M.D, Colorado Blood Cancer Institute and Presbyterian St. Luke Hospital, believes that the results of the five-year clinical trial offer a promise for long-term treatment, even though more research may be needed. If larger studies confirm these findings, HDIT/HCT might just be the therapeutic option that patients who have relapsing-remitting multiple sclerosis, have been waiting for.
About Dr. Shiva Gopal Vasishta
An M.D, Shiva Gopal Vasishta is a practicing neurologist in Voorhees, New Jersey. He has been practicing for 40 years. He studied at Government Medical College in 1979 and finished his residency at Boston City Hospital. Shiva Gopal Vasishta also practices psychiatry. Presently, he is practicing at Neurodiagnostic Associate, besides having an affiliation with Kennedy Health System Cherry Hill Campus.
Dr. Shiva Gopal Vasishta has the necessary licensing that permits him to work in New Jersey. The fact that he participates in Medicare programs means that he accepts the amount of money approved by Medicare without billing patients additional payments. Shiva Gopal Vasishta is board certified in neurology and avails his services in both English and Spanish.